title: Amphotericin B deoxycholate: no significant advantage of a 24 h over a 6 h infusion schedule.
authors.forename: Philipp
authors.initials: P
authors.lastname: Altmannsberger
authors.forename: Ernst
authors.initials: E
authors.lastname: Holler
authors.forename: Reinhard
authors.initials: R
authors.lastname: Andreesen
authors.forename: Stefan W
authors.initials: SW
authors.lastname: Krause
mesh_terms: D000666:Amphotericin B / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000935:Antifungal Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D003840:Deoxycholic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004338:Drug Combinations; D006402:Hematologic Diseases / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D007262:Infusions, Intravenous; D007668:Kidney / Q000187:drug effects; D008875:Middle Aged; D009181:Mycoses / Q000517:prevention & control*; D016896:Treatment Outcome
chemical_list: D000935:Antifungal Agents; D004338:Drug Combinations; D003840:Deoxycholic Acid; D000666:Amphotericin B; C059765:amphotericin B, deoxycholate drug combination